(Reuters) - Exelixis Inc's drug to treat a rare form of thyroid cancer met the main goal of a late-stage study, prompting the company to look to an accelerated approval process that could bring the drug to market within a year.
Shares of San Francisco-based Exelixis were up 18 percent at $7.09 in heavy trading on Monday on Nasdaq. They had touched a high of $7.53 earlier in the day.
...
↧